JP2022512965A5 - - Google Patents

Info

Publication number
JP2022512965A5
JP2022512965A5 JP2021525039A JP2021525039A JP2022512965A5 JP 2022512965 A5 JP2022512965 A5 JP 2022512965A5 JP 2021525039 A JP2021525039 A JP 2021525039A JP 2021525039 A JP2021525039 A JP 2021525039A JP 2022512965 A5 JP2022512965 A5 JP 2022512965A5
Authority
JP
Japan
Prior art keywords
formula
alkyl
absent
methacrylate
linking group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021525039A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512965A (ja
JP7588855B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/059711 external-priority patent/WO2020093061A1/en
Publication of JP2022512965A publication Critical patent/JP2022512965A/ja
Publication of JP2022512965A5 publication Critical patent/JP2022512965A5/ja
Priority to JP2024158746A priority Critical patent/JP2024175018A/ja
Application granted granted Critical
Publication of JP7588855B2 publication Critical patent/JP7588855B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021525039A 2018-11-02 2019-11-04 治療方法 Active JP7588855B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024158746A JP2024175018A (ja) 2018-11-02 2024-09-13 治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862755196P 2018-11-02 2018-11-02
US62/755,196 2018-11-02
PCT/US2019/059711 WO2020093061A1 (en) 2018-11-02 2019-11-04 Therapeutic methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024158746A Division JP2024175018A (ja) 2018-11-02 2024-09-13 治療方法

Publications (3)

Publication Number Publication Date
JP2022512965A JP2022512965A (ja) 2022-02-07
JP2022512965A5 true JP2022512965A5 (enExample) 2022-11-07
JP7588855B2 JP7588855B2 (ja) 2024-11-25

Family

ID=70463345

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525039A Active JP7588855B2 (ja) 2018-11-02 2019-11-04 治療方法
JP2024158746A Pending JP2024175018A (ja) 2018-11-02 2024-09-13 治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024158746A Pending JP2024175018A (ja) 2018-11-02 2024-09-13 治療方法

Country Status (14)

Country Link
US (1) US20220031847A1 (enExample)
EP (1) EP3873530A4 (enExample)
JP (2) JP7588855B2 (enExample)
KR (1) KR20210120988A (enExample)
CN (1) CN113365662A (enExample)
AU (1) AU2019370563B2 (enExample)
BR (1) BR112021008449A2 (enExample)
CA (1) CA3118142A1 (enExample)
EA (1) EA202191210A1 (enExample)
IL (1) IL282794B2 (enExample)
MX (1) MX2021005130A (enExample)
NZ (1) NZ776256A (enExample)
SG (1) SG11202104461XA (enExample)
WO (1) WO2020093061A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109312342A (zh) * 2016-04-11 2019-02-05 阿布特斯生物制药公司 靶向核酸偶联物组合物
US20220062323A1 (en) * 2018-11-02 2022-03-03 Arbutus Biopharma Corporation Bivalent targeted conjugates
EP4007811A2 (en) * 2019-08-01 2022-06-08 Alnylam Pharmaceuticals, Inc. Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof
US20220387600A1 (en) * 2019-12-06 2022-12-08 Genevant Sciences Gmbh Conjugates and methods for treating liver fibrosis
KR20220119052A (ko) * 2019-12-20 2022-08-26 아뷰터스 바이오파마 코포레이션 합성 공정 및 중간체
CN114901360A (zh) 2019-12-20 2022-08-12 库瑞瓦格股份公司 用于递送核酸的新型脂质纳米颗粒
KR20230118715A (ko) 2020-10-14 2023-08-11 조지 메이슨 리서치 파운데이션 인코포레이티드 이온화 가능 지질 및 이의 제조 및 사용 방법
EP4355756A4 (en) 2021-06-18 2025-08-13 Hongene Biotech Corp N-ACETYLGALACTOSAMINE FUNCTIONALIZED NUCLEOSIDES
JP2024532271A (ja) 2021-08-30 2024-09-05 ホンジーン バイオテック コーポレイション 官能化n-アセチルガラクトサミンアナログ
CN117940158A (zh) 2021-09-03 2024-04-26 库瑞瓦格欧洲公司 用于核酸递送的包含磷脂酰丝氨酸的新型脂质纳米颗粒
WO2023097186A1 (en) * 2021-11-24 2023-06-01 The Regents Of The University Of California Compositions and methods for enhancing visual function
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
CN118591552A (zh) * 2022-01-30 2024-09-03 成都凌泰氪生物技术有限公司 一种配体、其制备方法及应用
CA3246334A1 (en) * 2022-03-25 2023-09-28 Shanghai Hansoh Biomedical Co., Ltd. BICYCLIC HETEROCYCLES AND THEIR LIGANDS FOR TARGETED ADMINISTRATION OF THERAPEUTIC AGENTS
US20250215042A1 (en) * 2022-04-01 2025-07-03 Genevant Sciences Gmbh Mannose-targeted compositions
JP2025531872A (ja) * 2022-09-12 2025-09-25 ジェネバント サイエンシズ ゲーエムベーハー 標的指向組成物
EP4342460A1 (en) 2022-09-21 2024-03-27 NovoArc GmbH Lipid nanoparticle with nucleic acid cargo
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
WO2024125597A1 (en) 2022-12-14 2024-06-20 Providence Therapeutics Holdings Inc. Compositions and methods for infectious diseases
CN116535449B (zh) * 2023-03-22 2025-09-16 华东理工大学 一种糖基没食子酸类衍生物及其制备方法与在制备乳腺癌靶向诊疗材料中的应用
CN118993970B (zh) * 2023-05-17 2025-12-23 苏州富士莱医药股份有限公司 一种l96侧链化合物的制备方法
CN119219716A (zh) * 2023-06-30 2024-12-31 上海维申医药有限公司 新型GalNAc的靶向递送片段及其制备和应用
GB202311334D0 (en) * 2023-07-24 2023-09-06 Astrazeneca Ab Multivalent cargo-carrying complexes and uses thereof
CN121752256A (zh) 2023-09-01 2026-03-27 诺沃阿克有限责任公司 具有核酸负载物和可电离脂质的脂质纳米颗粒
CN117624266A (zh) * 2023-10-19 2024-03-01 弘亮(上海)生物医药科技有限公司 一种肝靶向化合物及其寡核苷酸缀合物、偶联方法与应用
GB202408360D0 (en) 2024-06-11 2024-07-24 Cancer Research Tech Ltd Tumour sensitisation
CN121045314B (zh) * 2025-10-31 2026-04-14 南昌市第一医院 一种靶向降解hmgb1的化合物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2404136T3 (es) * 2008-05-13 2013-05-24 University Of Washington Ensamblajes micelares
WO2011062965A2 (en) * 2009-11-18 2011-05-26 University Of Washington Through Its Center For Commercialization Targeting monomers and polymers having targeting blocks
AU2014296278C1 (en) * 2013-07-30 2023-02-02 Genevant Sciences Gmbh Block copolymers and their conjugates or complexes with oligonucleotides
CN114642735A (zh) * 2015-01-21 2022-06-21 菲泽尔克斯公司 用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统
CN109312342A (zh) * 2016-04-11 2019-02-05 阿布特斯生物制药公司 靶向核酸偶联物组合物
US11684584B2 (en) * 2016-12-30 2023-06-27 Genevant Sciences Gmbh Branched peg molecules and related compositions and methods
WO2018191278A2 (en) * 2017-04-11 2018-10-18 Arbutus Biopharma Corporation Targeted compositions

Similar Documents

Publication Publication Date Title
JP6833844B2 (ja) アルギナーゼ活性を阻害する組成物及び方法
JP2024175018A5 (enExample)
AU2023248123B2 (en) Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
RU2011150787A (ru) КОНЪЮГАТ миРНК И СПОСОБ ЕГО ПОЛУЧЕНИЯ
JP2013523896A5 (enExample)
JP2010523582A5 (enExample)
CA2745302A1 (en) Zwitterionic polymers with therapeutic moieties
RU2012144555A (ru) Конъюгированный фактор свертывания крови viii
JP7764041B2 (ja) 脳腫瘍における改善された血液脳関門浸透性及び滞留性を備えた、スケーラブルなチロインテグリンアンタゴニストの組成物
JP2013525414A5 (enExample)
RU2012144554A (ru) КОНЪЮГИРОВАННЫЙ ФАКТОР СВЕРТЫВАНИЯ КРОВИ VIIa
AU2014266254B2 (en) Polymeric micelle pharmaceutical composition
JP2014519507A5 (enExample)
KR20140024833A (ko) 신규한 시티딘계 대사길항제의 고분자 유도체
RU2013156939A (ru) Способ лечения лихорадки денге
TW201143797A (en) Easily collapsible polymer micelle composition
EP3710061A1 (fr) Prodrogues polymères et leur administration sous-cutanee et/ou intramusculaire
JP7376694B2 (ja) 再生可能資源に由来するポリマーおよび組成物
WO2022168967A1 (ja) 新規なコポリマー
RU2012105579A (ru) Способ конъюгирования полимера с белком, конъюгат, полученный указанным способом, композиция и лекарственное средство на его основе и способ лечения с их помощью
WO2011049042A1 (ja) 腹腔内投与用の抗がん剤含有ブロック共重合体、ミセル調製物及びそれを有効成分とする癌治療薬
JP6837962B2 (ja) 活性薬剤の送達のための両親媒性ブロックコポリマー
JP2008229213A (ja) 生体適合性接着剤組成物
CN109908356B (zh) 负载抗肿瘤药物的氰基丙烯酸酯材料
TW202348600A (zh) 含氮鏈狀化合物、製備方法、包含其的組成物和應用